Associated Papers
Precision oncology in Bulgaria: a prospective study of metastatic colorectal cancer patients.
Dimitrov G et al.
Cancer Treatment and Research Communications, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases.
Park SS et al.
Annals of Laboratory Medicine, 2025
Phospholipase Cδ-4 (PLCδ4) Acts as a Nuclear Player to Influence Cyclin B Expression in the Embryonal Rhabdomyosarcoma Cell Lines RD and A204.
Salucci S et al.
Biomolecules, 2024
Genetics of brain arteriovenous malformations and cerebral cavernous malformations.
Hongo H et al.
Journal of Human Genetics, 2023
Peptides That Block RAS-p21 Protein-Induced Cell Transformation.
Pincus MR et al.
Biomedicines, 2023
AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology.
Tsimberidou AM et al.
Cell & Bioscience, 2022
Anticancer drug resistance: An update and perspective.
Nussinov R et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2021
Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study.
Zhang H et al.
Oncology Letters, 2021
Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
Poulsen TS et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2021
Mutation profiling of cancer drivers in Brazilian colorectal cancer.
Dos Santos W et al.
Scientific Reports, 2019
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Shaukat I et al.
Human Pathology, 2019
Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
Chay WY et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2018
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.
Gong J et al.
Oncotarget, 2017
NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing.
Chang PY et al.
Oncotarget, 2016
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC et al.
Oncotarget, 2016
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
Russo M et al.
Cancer Discovery, 2016
A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D et al.
Oncotarget, 2015
Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcomas.
Liu CX et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H et al.
International Journal of Clinical Oncology, 2013
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Weigelt B et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R et al.
Thyroid : Official Journal of the American Thyroid Association, 2013
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
Kim JE et al.
Bmc Cancer, 2012
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
Fumagalli D et al.
Bmc Cancer, 2010
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E et al.
Molecular Cancer Therapeutics, 2010
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.
Smith G et al.
British Journal of Cancer, 2010
A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes.
Palmirotta R et al.
In Vivo (athens, Greece), 0